Keil MF, Stratakis CA. Pituitary tumors in childhood: Update of diagnosis, treatment and molecular genetics. Expert Rev Neurother. 2008 Apr; 8(4): 563-74.
Daly AF, Tichomirowa MA, Petrossians P, Heliövaara E, Jaffrain-Rea ML, Barlier A et al. Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: An international collaborative study. J Clin Endocrinol Metab. 2010 Nov; 95(11):E373-83.
Stratakis CA, Tichomirowa MA, Boikos S, Azevedo MF, Lodish M, Martari M et al. The role of germline AIP, MEN1, PRKAR1A, CDKN1B and CDKN2C mutations in causing pituitary adenomas in a large cohort of children, adolescents, patients with genetic syndromes. Clin Genet. 2010 Nov; 78(5): 457-63.
Cazabat L, Bouligand J, Salenave S, Bernier M, Gaillard S, Parker F et al. Germline AIP mutations in apparently sporadic pituitary adenomas: Prevalence in a prospective single-center cohort of 443 patients. J Clin Endocrinol Metab. 2012 Apr; 97(4):E663-70.
Hernández-Ramírez LC, Gabrovska P, Dénes J, Stals K, Trivellin G, Tilley D et al.; International FIPA Consortium. Landscape of Familial Isolated and Young-Onset Pituitary Adenomas: Prospective Diagnosis in AIP Mutation Carriers. J Clin Endocrinol Metab. 2015 Sep; 100(9):E1242-54.
Daly AF, Vanbellinghen JF, Khoo SK, Jaffrain-Rea ML, Naves LA, Guitelman MA et al. Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: Analysis in 73 families. J Clin Endocrinol Metab. 2007 May; 92(5): 1891-6.
Kasuki L, Vieira Neto L, Wildemberg LE, Colli LM, de Castro M, Takiya CM et al. AIP expression in sporadic somatotropinomas is a predictor of the response to octreotide LAR therapy independent of SSTR2 expression. Endocr Relat Cancer. 2012 May; 19(3):L25-9.
Chahal HS, Trivellin G, Leontiou CA, Alband N, Fowkes RC, Tahir A et al. Somatostatin analogs modulate AIP in somatotroph adenomas: The role of the ZAC1 pathway. J Clin Endocrinol Metab. 2012 Aug; 97(8):E1411-20.
van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L et al. Longterm treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet. 2001 Nov; 358(9295): 1754-9.
van der Lely AJ, Biller BM, Brue T, Buchfelder M, Ghigo E, Gomez R et al. Long-term safety of pegvisomant in patients with acromegaly: Comprehensive review of 1288 subjects in ACROSTUDY. J Clin Endocrinol Metab. 2012 May; 97(5): 1589-97.
Personnier C, Cazabat L, Bertherat J, Gaillard S, Souberbielle JC, Habrand JL et al. Clinical features and treatment of pediatric somatotropinoma: Case study of an aggressive tumor due to a new AIP mutation and extensive literature review. Horm Res Paediatr. 2011; 75(6): 392-402.
Rostomyan L, Daly AF, Petrossians P, Nachev E, Lila AR, Lecoq AL et al. Clinical and genetic characterization of pituitary gigantism: An international collaborative study in 208 patients. Endocr Relat Cancer. 2015 Oct; 22(5): 745-57.
Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Murad MH, Utz A et al.; Endocrine Society. Acromegaly: An endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014 Nov; 99(11): 3933-51.
Padovani L, André N, Constine LS, Muracciole X. Neurocognitive function after radiotherapy for paediatric brain tumours. Nat Rev Neurol. 2012 Oct; 8(10): 578-88.
